RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024,...
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...
Novo Nordisk’s Mim8 for Haemophilia A Exceeds Endpoints in Late-Stage Trial
Denmark-based healthcare company Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Roche and Genprex Initiate Phase I Trial Combining Tecentriq and Reqorsa for ES-SCLC
Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in...
BeiGene’s Brukinsa Secures Conditional Approval in China for R/R Follicular Lymphoma
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China,...
AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies
AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio...
MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA...
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
B&K Co., Ltd, known as Bio-Bank Corp., a biopharmaceutical company specializing in protein drug development...
Novartis Shakes Up Executive Suite with Appointments and Transitions
The president of Novartis (NYSE: NVS)’ International Business Unit has this week declared a series...
Healingovation Raises Over RMB 60 Million in Pre-Series A++ Round for Aquablation Surgical Robot
Healingovation, a Beijing-based innovator in surgical robots and intelligent diagnostic and therapeutic equipment, has reportedly...
Brii Biosciences’ HBV Drug Candidates Receive NMPA’s Breakthrough Therapy Designations
Brii Biosciences Ltd (HKG: 2137) has announced that two of its hepatitis B virus (HBV)...
HutchMed’s HMPL-306 Advances to Phase III Trial in R/R AML Patients
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the commencement of the RAPHAEL study,...
Zai Lab’s ROS1 Inhibitor Augtyro Earns NMPA Nod for Advanced NSCLC Treatment
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...
NMPA Accepts Jiangsu Yahong Meditech’s Application for Cervical HSIL Treatment Cevira
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments in...
Mabwell’s 9MW2821 ADC for Triple Negative Breast Cancer Accepted for Review by NMPA
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Huadong Medicine’s EGFR Inhibitor Mefatinib for NSCLC Accepted by NMPA for Review
Huadong Medicine Co., Ltd (SHE: 000963), a leading pharmaceutical company based in China, has announced...
Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close...